Immunotec Announces New CEO
News May 20, 2013
Mr. Orr has served since March 2009 as Executive Director of the Direct Selling Education Foundation, where he held ultimate responsibility for the Foundation's programs and activities. Since 2001, he has provided his proven and successful expertise by active participation as a board member and advisor in a variety of publicly traded and privately held organizations ranging from over a billion dollars in revenue to start-ups. Mr. Orr served as President and Chief Executive Officer of Shaklee Corporation (1993-2000), where he was responsible for the performance of the company's diverse business units. Shaklee, then a $700m revenue company, included the brand names of Harry and David, Jackson and Perkins, and Shaklee. Mr. Orr has been a director of Immunotec since 2006.
Mr. Orr is a seasoned professional with 23 years of experience in the direct selling field. Additionally, his work history includes extensive leadership responsibility in the financial services and computer industries. Mr. Orr was selected as Chief Executive Officer based on a track record leading complex organizations, as well as strong executive and personal qualities. Mr. Orr earned a BA in Psychology from Wesleyan University and an MBA from the University of Connecticut.
In 2005, Mr. Orr received the distinctive Circle of Honor Award from the Direct Selling Education Foundation. In 2007, he was honored by the Direct Selling Association with its prestigious Hall of Fame Award.
Mr. Orr will work out of the Corporation's offices in Vaudreuil, Quebec once all immigration approvals have been obtained.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.